Results 241 to 250 of about 5,946,067 (288)

Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility.

J Clin Endocrinol Metab
Stoffers AJ, Mancilla EE, Levine MA, Mayer M, Monk HM, Rosano J, Weber DR.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Zoledronic-acid

Reactions Weekly, 2023
K. Wellington, K. Goa
semanticscholar   +3 more sources

Zoledronic acid

Expert Opinion on Drug Safety, 2010
Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions.The incidence ...
Robert, Coleman, Roger, Burkinshaw, Matthew, Winter, Helen, Neville-Webbe, Jim, Lester, Emma, Woodward, Janet, Brown   +6 more
  +5 more sources

Zoledronic Acid-Gadolinium Coordination Polymer Nanorods for Improved Tumor Radioimmunotherapy by Synergetically Inducing Immunogenic Cell Death and Reprogramming the Immunosuppressive Microenvironment.

ACS Nano, 2021
Radiation therapy can potentially elicit a systemic immune response and cause the regression of nonirradiated tumors, and the checkpoint blockade immunotherapies have been introduced to improve their clinical response rate.
Zhusheng Huang, Dan Yao, Qingsong Ye, Haojie Jiang, Rong Gu, Changwei Ji, Jinhui Wu, Yiqiao Hu, A. Yuan   +8 more
semanticscholar   +1 more source

Zoledronic acid‐induced oxidative damage and endoplasmic reticulum stress‐mediated apoptosis in human embryonic kidney (HEK‐293) cells

Journal of biochemical and molecular toxicology, 2022
Zoledronic acid, a nitrogen‐containing bisphosphonate drug, is used for the treatment of osteoporosis, Paget's disease of bone, and tumor‐induced osteolysis.
M. Kara, Tuğçe Boran, E. Öztaş, A. T. Jannuzzi, Sibel Özden, G. Özhan   +5 more
semanticscholar   +1 more source

Zoledronic Acid

Drugs, 2001
Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro.
S M, Cheer, S, Noble
openaire   +2 more sources

Zoledronic Acid Substantially Improves Bone Microarchitecture and Biomechanical Properties After Rotator Cuff Repair in a Rodent Chronic Defect Model

American Journal of Sports Medicine, 2020
Background: Bone mineral density at the humeral head is reduced in patients with chronic rotator cuff tears. Bone loss in the humeral head is associated with repair failure after rotator cuff reconstruction. Bisphosphonates (eg, zoledronic acid) increase
J. Schanda, C. Keibl, P. Heimel, X. Monforte, S. Tangl, X. Feichtinger, A. Teuschl, A. Baierl, C. Muschitz, H. Redl, C. Fialka, R. Mittermayr   +11 more
semanticscholar   +1 more source

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.

The Lancet Oncology, 2019
BACKGROUND The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss, but
J. Denham, D. Joseph, D. Lamb, N. Spry, G. Duchesne, J. Matthews, C. Atkinson, K. Tai, D. Christie, L. Kenny, S. Turner, N. Gogna, T. Diamond, B. Delahunt, C. Oldmeadow, J. Attia, A. Steigler   +16 more
semanticscholar   +1 more source

Differences between zoledronic acid and denosumab for breast cancer treatment

Journal of Bone and Mineral Metabolism, 2023
Takashi Ishikawa
semanticscholar   +1 more source

Zoledronic-acid

Reactions Weekly, 2017
  +8 more sources